3rd Annual Guggenheim Healthcare Innovation Conference
Logotype for Yarrow Bioscience Inc

Yarrow Bioscience (YARW) 3rd Annual Guggenheim Healthcare Innovation Conference summary

Event summary combining transcript, slides, and related documents.

Logotype for Yarrow Bioscience Inc

3rd Annual Guggenheim Healthcare Innovation Conference summary

9 Nov, 2026

Strategic rationale and market

  • YB-101 is a monoclonal antibody designed to block TSHR directly, targeting the disease pathway in both Graves’ disease and thyroid eye disease (TED).

  • Graves’ disease and TED are driven by autoantibodies that overstimulate TSHR in the thyroid and eye; the disease is polyclonal, with varied antibody isotypes.

  • TSHR blockade may address both thyroid and eye disease; IGF-1R inhibitors validate the potential for eye improvement but are limited by safety concerns and do not address thyroid disease.

  • Graves’ disease affects 1% of the U.S. population; 40% of patients develop TED, and 20%-25% develop moderate-to-severe TED requiring intervention.

  • Development aims to enable broad, potentially earlier treatment; the TED goal is IGF-1R-like efficacy with a more favorable risk-benefit profile.

Clinical evidence and safety

  • China Phase I single-ascending-dose TED study showed favorable safety, with no dose-limiting toxicities; thyroid hormone changes were the main safety difference from placebo.

  • After a single dose, T4 and T3 declined within 2-3 days and TSH increased within 5 days, indicating rapid reversal of thyroid hormone balance.

  • Small-sample Phase I data showed dose-dependent proptosis responses differentiated from placebo, viewed as proof of mechanism and support for multiple-dose evaluation.

  • Hypothyroidism is expected on-target pharmacology; prompt T4 replacement is intended to make it transient while maintaining normal thyroid hormone levels.

  • For Graves’ disease, management views the uncontrolled FcRn study’s 56% euthyroid/off-ATD result as a reference point and aims to do better; TED aspirations target IGF-1R-like efficacy.

Graves’ and TED development plans

  • Direction GD Phase II-A is a four-cohort, placebo-controlled study with dosing every 8 weeks; the 6-month primary endpoint is the proportion euthyroid and off antithyroid drugs (ATDs).

  • Participants must have stable thyroid function on ATDs for at least 3 months; the protocol uses a structured ATD taper and initiates T4 based on thyroid hormone changes.

  • Initial cohorts use 180 mg and 270 mg every 8 weeks; tentative later cohorts are 400 mg every 8 weeks and 200 mg every 4 weeks, subject to data review.

  • First patient was dosed in July; Phase II-A data are expected in 2H 2027, with all four cohorts planned for a combined disclosure.

  • China TED Phase I-B multiple-ascending-dose data are expected in 2H 2027; Phase II-B Graves’ doses will be selected using Phase II-A results.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Yarrow Bioscience